News & Updates

In the final analysis of the phase III PROTEUS trial, perioperative apalutamide + androgen deprivation therapy (APA+ADT) improves the curative success of radical prostatectomy (RP) in men with high-risk localized or locally advanced prostate cancer (HR LPC/LAPC).

Individuals with high alcohol consumption are at increased risk of colorectal cancer (CRC), reports a study, which shows that alcohol intake may trigger colorectal carcinogenesis through mechanisms operating across major molecular pathways for CRC.

Daraxonrasib—an oral, potent RAS(ON) multi-selective, tri-complex inhibitor—demonstrates unprecedented survival benefits in individuals with previously treated metastatic pancreatic adenocarcinoma (mPDAC) in the landmark phase III RASolute 302 study.

Adding cabozantinib to nivolumab and ipilimumab as first-line therapy, compared with placebo, results in prolonged progression-free survival (PFS) among untreated patients with advanced renal cell carcinoma (RCC), with no new safety signals seen, as shown by the results of the phase III COSMIC-313 study.